New Aneuploidy Study Findings Have Been Reported from Royan Institute of Reproductive Biomedicine (Aneuploidy Rate and Stemness In Low-level Mosaic Human Embryonic Stem Cells In the Presence/absence of Bortezomib, Paclitaxel and Lapatinib).

A study conducted by the Royan Institute of Reproductive Biomedicine in Tehran, Iran, investigated the effect of three anticancer drugs (bortezomib, paclitaxel, and lapatinib) on the aneuploidy rate in human embryonic stem cells (hESCs). The researchers found that treatment with these drugs did not have a negative effect on pluripotency, and aneuploid cells were dominant in both the treated and control groups. The insensitivity of aneuploid cells in the treatment groups may be due to the specific characteristics of each cell line and the proliferative superiority of cells with trisomies 12 and 17. This research has been peer-reviewed and published in Cells Tissues Organs. [Extracted from the article]

Copyright of Stem Cell Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)